Unlock the Editor’s Digest for free
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.
France’s financial prosecutor has opened a preliminary investigation of pharmaceutical group Sanofi over allegations of market manipulation related to the launch of its hit drug Dupixent in 2017.
The prosecutor’s office, which opened the probe in March, is looking into allegations of “dissemination of false or misleading information and price manipulation” concerning financial communications by the group, according to a judicial official. The next step may or may not be a formal investigation, depending on the evidence.
Sanofi said: “We stand by the accuracy of our accounts,” adding that it “reserves the right to take legal action against any false or defamatory allegations”. The probe was first reported by French publication La Lettre A.
Dupixent, which is used to treat asthma and eczema, is Sanofi’s best-selling product. Sales increased 35…